

## **COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron**

*Nungruthai Suntronwong<sup>a</sup>, Ritthideach Yorsaeng<sup>a</sup>, Jiratchaya Puenpa<sup>a</sup>, Chompoonut Auphimai<sup>a</sup>, Thanunrat Thongmee<sup>a</sup>, Preeyaporn Vichaiwattana<sup>a</sup>, Sitthichai Kanokudom<sup>a</sup>, Thaneeya Duangchinda<sup>b</sup>, Warangkana Chantima<sup>c,d</sup>, Pattarakul Pakchotanon<sup>b</sup>, Suvichada Assawakosri<sup>a</sup>, Pornjarim Nilyanimit<sup>a</sup>, Sirapa Klinfueng<sup>a</sup>, Lakkhana Wongsrisang<sup>a</sup>, Donchida Srimuan<sup>a</sup>, Thaksaporn Thatsanatorn<sup>a</sup>, Natthinee Sudhinaraset<sup>a</sup>, Nasamon Wanlapakorn<sup>a</sup>, Yong Poovorawan<sup>a,e\*</sup>*

<sup>a</sup>Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

<sup>b</sup>Molecular Biology of Dengue and Flaviviruses Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Development Agency, NSTDA, Pathum Thani 12120, Thailand

<sup>c</sup>Division of Dengue Hemorrhagic Fever Research, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

<sup>d</sup>Siriraj Center of Research Excellence in Dengue and Emerging Pathogens, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

<sup>e</sup>Royal Society of Thailand (FRS(T)), Sanam Sueapa, Dusit, Bangkok 10330, Thailand

\*Corresponding author: Yong Poovorawan, MD

Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

Email: [yong.p@chula.ac.th](mailto:yong.p@chula.ac.th)

1 **COVID-19 breakthrough infection after inactivated vaccine induced robust**  
2 **antibody responses and cross-neutralization of SARS-CoV-2 variants, but**  
3 **less immunity against omicron**

4  
5 **Abstract**

6 The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants  
7 and the waning of immunity in vaccinated individuals is resulting in increased numbers of  
8 SARS-CoV-2 breakthrough infections. This study investigated binding antibody responses  
9 and neutralizing activities against SARS-CoV-2 variants in patients with COVID-19 who had  
10 been fully vaccinated with CoronaVac ( $n = 78$ ), individuals who had been fully vaccinated  
11 with CoronaVac but had not contracted COVID-19 ( $n = 170$ ), and individuals who had  
12 received AZD1222 as a third vaccination ( $n = 210$ ). Breakthrough infection was generally  
13 detected approximately 88 days after the second CoronaVac vaccination (interquartile range  
14 68–100) days. Blood samples were collected at median of 34 days after infection. Binding  
15 antibody levels in sera from patients with breakthrough infection were significantly higher  
16 than those in individuals who had received AZD1222 as a third vaccination. However,  
17 neutralizing activities against wild-type and variants including alpha (B.1.1.7), beta  
18 (B.1.351), and delta (B.1.617.2) were comparable in patients with breakthrough infections  
19 and individuals who received a third vaccination with AZD1222, which activities are  
20 exceeding 90%. Omicron (B.1.1.529) was neutralized less effectively by serum from  
21 breakthrough infection patients, with a 6.3-fold reduction compared to delta variants. The  
22 study suggests that breakthrough infection after two doses of an inactivated vaccine can  
23 induce neutralizing antibody against omicron. Further investigation is needed to assess the  
24 long-term persistence of antibody against omicron variant.

25  
26 **Keywords:** breakthrough, infection, SARS-CoV-2, omicron

27

28 Since the commencement of the coronavirus disease 2019 (COVID-19) outbreak at the  
29 end of 2019, there have been more than 313 million cases of infection [1]. Vaccines are an  
30 available tool to prevent and control this threat. Reduced viral susceptibility to  
31 vaccine-induced antibodies due to the emergence of severe acute respiratory syndrome  
32 coronavirus 2 (SARS-CoV-2) variants, together with the waning of vaccine-induced  
33 immunity, is increasing the incidence of COVID-19 breakthrough infection after

34 vaccination [2,3]. Notably however, the study of immunogenicity and neutralization of  
35 SARS-CoV-2 variants, particularly omicron (B.1.1.529), is limited [4]. This study aims to  
36 determine antibody levels and cross-neutralization in patients with SARS-CoV-2  
37 breakthrough infection following two doses of CoronaVac compared with those in uninfected  
38 individuals who received two doses of CoronaVac and those who received AZD1222 as third  
39 vaccination.

40  
41 Patients who had been completely vaccinated with two doses of CoronaVac then  
42 subsequently became infected with SARS-CoV-2 as determined via a positive polymerase  
43 chain reaction (PCR) test were recruited at the Center of Excellence in Clinical Virology  
44 between 21 April and 20 September, 2021. The SARS-CoV-2 variants circulating in Thailand  
45 during the study period were alpha (April to June) and delta (July to September) (Figure 1).  
46 Controls were unexposed SARS-CoV-2 individuals who had been fully vaccinated with two  
47 doses of CoronaVac and screened with anti-nucleocapsid IgG as previously described [5].  
48 Fully vaccinated CoronaVac individuals who received AZD1222 as a third vaccination were  
49 also analysed [6].

50 All sera were tested for SARS-CoV-2-specific binding antibody responses via  
51 enzyme-linked immunosorbent assays, including total immunoglobulin (Ig) against the  
52 SARS-CoV-2 receptor-binding domain (RBD), and IgG and IgA specific for SARS-CoV-2  
53 protein. Neutralizing activity against wild-type SARS-CoV-2 and variants including alpha  
54 (B.1.1.7; N501Y), beta (B.1.351; K417N, E484K, and N501Y), and delta (B.1.617.2; L452R  
55 and T478K) was assessed using a cPass<sup>TM</sup> SAR-CoV-2 neutralizing antibody detection kit  
56 (GenScript, Jiangsu, China) in accordance with the manufacturer's instructions. Neutralizing  
57 antibody titres against delta (B.1.617.2) and omicron (B.1.1.529) were determined using the  
58 focus reduction neutralization test as previously described [7].

59 Geometric mean antibody titres with 95% confidence intervals (CIs) were calculated, and  
60 neutralizing activities were expressed as medians and interquartile ranges (IQRs). Differences  
61 were assessed using the Kruskal-Wallis method with Dunn's correction. GraphPad Prism was  
62 used to generate figures, and statistics were analysed using SPSS. Statistical significance was  
63 defined as  $p < 0.05$ . The study protocol was conducted in accordance with the Declaration of  
64 Helsinki and Good Clinical Practice principles, and it was approved by the Research Ethics  
65 Committee of the Faculty of Medicine, Chulalongkorn University (IRB numbers 835/64,  
66 192/64, and 546/64). All participants provided written informed consent.

67

68 The group who had been vaccinated with two doses of CoronaVac and subsequently  
69 became infected with SARS-CoV-2 contained 78 patients with a mean age of 34.2 years; 58  
70 women (74.4%) and 20 men (25.6%). The median time between the second CoronaVac  
71 vaccination and breakthrough infection was 88 days (IQR 68–100 days). Blood samples were  
72 collected at 34 days (IQR 29–43) post infection. The group who had been fully vaccinated  
73 with CoronaVac but remained unexposed to SARS-CoV-2 infection contained 170  
74 participants with a mean age of 42.3 years; 89 women (52.4%) and 81 men (47.6%). The  
75 blood samples were collected at median of 29 days (IQR 27–31) post a second dose  
76 vaccination. The group who had been fully vaccinated with CoronaVac then received  
77 AZD1222 as a third vaccination contained 210 participants with a mean age of 40 years; 151  
78 women (71.9%) and 59 men (28.1%). The median time between blood sampling and a third  
79 dose was 28 days (IQR 20–32) (Supplementary Table 1).

80 Total RBD-specific Ig was significantly increased in patients with breakthrough infection  
81 (18154 units per millilitre (U/mL); 95% CI 13506–24402 U/mL) compared to fully  
82 vaccinated individuals without infection (98 U/mL; 95% CI 83–116 U/mL) (Figure 1A).  
83 RBD-specific Ig was higher in participants with breakthrough infection than in those who  
84 received AZD1222 as a third vaccination (7947 U/mL; 95% CI 7277–8679). Anti-RBD IgG  
85 was significantly higher in patients with breakthrough infection (3668 binding antibody units  
86 per millilitre (BAU)/mL; 95% CI 2802–4802 BAU/mL) compared to fully vaccinated  
87 individuals (128 BAU/mL, 95% CI 114–144 BAU/mL) and those who received AZD1222 as  
88 a third vaccination (1492 BAU/mL, 95% CI 1367–1629 BAU/mL) (Figure 1B). Moreover,  
89 individuals with breakthrough infection (76/78; 97.4%) and those who received AZD1222 as  
90 a third vaccination (54/55; 98.2) were seropositive for anti-S1 IgA. Conversely, only 22/51  
91 (43.1%) of uninfected individuals who had been fully vaccinated with CoronaVac exhibited  
92 seropositivity for anti-S1 IgA (Figure 1C). These results indicate that patients with  
93 breakthrough infection could mount SARS-CoV-2-specific binding antibody responses.

94 Among breakthrough infection patients, 77/78 (98.7%) exhibited potential neutralization  
95 determined using sVNT against wild-type and SARS-CoV-2 variants. The median  
96 neutralizing activities in patients with breakthrough infection were 97.5% for wild-type,  
97 97.7% for alpha, 95.6% for beta, and 97.9% for delta (Supplementary Table 2). Neutralizing  
98 activities in breakthrough infection patients were significantly higher than those in unexposed  
99 individuals following complete CoronaVac vaccination ( $p < 0.001$ ) (Figure 1D–G).  
100 Compared to individuals who received AZD1222 as a third vaccination, in patients with  
101 breakthrough infection neutralizing activity was significantly higher for alpha ( $p = 0.02$ ) and

102 beta ( $p < 0.01$ ) variants, but not wild-type or delta variants. This suggests that variant cross-  
103 neutralization was improved after breakthrough infection. With respect to neutralizing  
104 antibody titres in sera from patients with breakthrough infection determined using live virus  
105 neutralization test, FRNT50, the geometric mean titres against delta were 1332 (95% CI 875–  
106 2026), whereas those against omicron were 212 (95% CI 142–316) (Figure 1H). This  
107 indicates that omicron is less effectively neutralized by serum antibody derived from  
108 breakthrough infection, with a 6.3-fold reduction compared to delta ( $p < 0.001$ ).

109

110 Our findings indicate that patients with breakthrough infection exhibited potent antibody  
111 responses, with both IgG and IgA titres exceeding those of individuals who received  
112 AZD1222 as a third vaccination. Notably the levels of anti-RBD IgG in almost all  
113 breakthrough patients were higher than 506 BAU/mL, which was the antibody level  
114 associated with 80% effectiveness against symptomatic alpha variant infection in a previous  
115 report [8]. Breakthrough infection increased neutralizing activity that cross-inhibited  
116 SARS-CoV-2 variants corresponding to wild-type, alpha, beta, and delta. In a previous study  
117 a similar result was observed in individuals who had received two mRNA SARS-CoV-2  
118 vaccinations and subsequently became infected [9]. This indicates that natural immunity and  
119 vaccine-induced immunity combined result in higher neutralizing potency than vaccination or  
120 infection alone [10].

121 Omicron variants are reportedly less susceptible to neutralization by existing immunity  
122 after natural infection [11], and vaccine-induced immunity [12]. Notably, sera from patients  
123 with breakthrough infection in the present study also exhibited less neutralizing activity  
124 against omicron than against delta. Consistent with a previous study [4] neutralization against  
125 omicron was 11.7-fold less than that for wild-type, and 7.9-fold less than that for delta. These  
126 results suggest immune escape of omicron in breakthrough infection patients. Reduced  
127 neutralizing potency against the omicron variant may be associated with many mutations in  
128 the spike protein [13].

129 The limitations of this study include a small sample size, and the SARS-CoV-2 variants  
130 that caused breakthrough infections were not identified. Omicron neutralization assays were  
131 not conducted using sera from unexposed individuals who had been fully vaccinated with two  
132 doses of CoronaVac or those who received AZD1222 as a third vaccination. Our finding  
133 highlights that breakthrough infection after two doses of inactivated vaccines can induce  
134 neutralizing antibody against omicron. Further investigation is needed to assess the long-term  
135 persistence of antibody against omicron variant.

136

## 137 **Acknowledgments**

138 This work was supported by the National Research Council of Thailand, the Health  
139 Systems Research Institute, the Center of Excellence in Clinical Virology of  
140 Chulalongkorn University, and King Chulalongkorn Memorial Hospital. National Center  
141 for Genetic Engineering and Biotechnology (BIOTEC Platform No. P2051613). Nungnuthai  
142 Suntronwong reports that financial support was also provided by the Second Century Fund  
143 Fellowship of Chulalongkorn University.

144

## 145 **Declaration of interest statement**

146 All authors have declared no competing interests.

147

## 148 **Data availability statement**

149 All data are available in the report. Additional information can be requested from the  
150 corresponding author.


151

## 152 **References**

- 153 [1] World Health Organization. WHO Coronavirus (COVID-19) Dashboard [Cited 2022  
154 January 14th]. Available from: <https://covid19.who.int>.
- 155 [2] Mizrahi B, Lotan R, Kalkstein N, et al. Correlation of SARS-CoV-2-breakthrough  
156 infections to time-from-vaccine. *Nat Commun.* 2021;12(1):1–5.
- 157 [3] Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 breakthrough infections in vaccinated  
158 health care workers. *N Engl J Med.* 2021;385(16):1474–1484.
- 159 [4] Ai J, Zhang H, Zhang Y, et al. Omicron variant showed lower neutralizing sensitivity than  
160 other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. *Emerg Microbes  
161 Infect.* 2021:1–24 (just-accepted). doi: 10.1080/22221751.2021.2022440.
- 162 [5] Wanlapakorn N, Suntronwong N, Phowatthanasathian H, et al. Safety and  
163 immunogenicity of heterologous and homologous inactivated and adenoviral-vectored  
164 COVID-19 vaccines in healthy adults. *medRxiv.* 2021. doi:10.1101/2021.11.04.21265908
- 165 [6] Yorsaeng R, Suntronwong N, Phowatthanasathian H, et al. Immunogenicity of a third  
166 dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in  
167 healthy adults. *Vaccine.* 2021;40(3):524–530.
- 168 [7] Supasa P, Zhou D, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B.1.1.7  
169 variant by convalescent and vaccine sera. *Cell.* 2021;184(8):2201–2211.

- 170 [8] Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and  
171 asymptomatic SARS-CoV-2 infection. *Nat Med*. 2021;27(11):2032–2040.
- 172 [9] Bates TA, McBride SK, Winders B, et al. Antibody response and variant cross-  
173 neutralization after SARS-CoV-2 breakthrough infection. *JAMA*. 2021. doi:  
174 10.1001/jama.2021.22898.
- 175 [10] Stamatatos L, Czartoski J, Wan YH, et al. mRNA vaccination boosts cross-variant  
176 neutralizing antibodies elicited by SARS-CoV-2 infection. *Science*. 2021. doi:  
177 10.1126/science.abg9175.
- 178 [11] Pulliam JR, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2  
179 reinfection associated with emergence of the Omicron variant in South Africa. *medRxiv*.  
180 2021. doi: 10.1101/2021.11.11.21266068.
- 181 [12] Roessler A, Riepler L, Bante D, et al. SARS-CoV-2 B. 1.1. 529 variant (Omicron)  
182 evades neutralization by sera from vaccinated and convalescent individuals. *medRxiv*. 2021.  
183 doi:10.1101/2021.12.08.21267491
- 184 [13] Sarkar R, Lo M, Saha R, et al. S glycoprotein diversity of the Omicron variant.  
185 *MedRxiv*. 2021. doi: 10.1101/2021.12.04.21267284.

186 **Figure legends**



187

188

189 **Figure 1: SARS-CoV-2-specific binding antibody responses and neutralizing activities.**

190 Immune response of individuals with SARS-CoV-2 breakthrough infection (CV+CV+

191 Infection) was compared to those with fully vaccinated CoronaVac vaccines without infection

192 (CV+CV) and those who received AZD1222 as third booster (CV+CV+AZ). Serum anti-

193 RBD Ig activity (A), anti-RBD IgG binding antibody units (B), and anti-S1 IgA (optical

194 density of the sample divided by a calibrator; S/C ratio) (C). Neutralizing activities against

195 wild-type (D), B.1.1.7-alpha (E), B.1.351-beta (F), and B.1.617.2-delta (G). Neutralizing

196 antibody titres against B.1.617.2-delta and B.1.1.529-omicron in serum samples from

197 individuals with breakthrough infection determined using focus reduction neutralization test

198 50 values (H). Geometric mean titres with 95% CIs and median values with IQRs are shown

199 as horizontal bars. Dotted lines indicate cut-off values, and grey shaded areas depict values

200 under the cut-off. Statistics were calculated using Kruskal–Wallis tests with Dunn’s post hoc

201 correction. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .